Integer Holdings Corporation: Navigating Growth and Prospering in the Medical Device Industry

187

On October 27th, Benchmark Co. analyst Robert Wasserman gave the medical device outsource manufacturer, Integer Holdings Corporation, a Buy rating with a $105 price target. This upbeat assessment comes on the heels of the company’s impressive Q3 earnings report and its strategic moves within the dynamic healthcare sector.

Promising Q3 Performance:

Integer reported a significant increase in its Q3 revenue, up 18% year-over-year, reaching $405 million. This substantial growth was led by robust performances in its two largest segments — Cardio and vascular and Cardiac Rhythm Management and neuromodulation. The 20% sales expansion in these areas reflects strong demand for electrophysiology, structural heart, and pre-market approval products.

Notably, the company also achieved 34% earnings per share (EPS) growth, its best in nearly two years, which significantly outpaced Wall Street’s expectations of approximately 16% EPS growth. This remarkable performance was attributed to margin expansion driven by supply chain improvements and successful cost-containment efforts.

Raised Full-Year Guidance:

Bolstering the robust Q3 results, Integer’s management increased its full-year guidance. The company anticipates market share gains, thus raising revenue growth guidance to 14%-16% (up from 11%-13%) and adjusted EPS to $4.47 to $4.67 (from $4.23 to $4.43). This revised 2023 EPS outlook points to 18% growth at the midpoint, following a 5% profit decline in 2022.

The market responded positively to these developments, with Integer shares surging more than 15% following the news. This growth trajectory aligns with a strategy that combines in-house expansion and strategic acquisitions, potentially sustaining the company’s momentum through 2024.

Integer’s Growth Drivers:

Integer’s core business revolves around manufacturing medical devices for a wide range of original equipment manufacturers (OEMs) across the healthcare sector. These products encompass drug delivery systems, implants, catheters, pulse generators, and surgical tools, among others. The company’s recent expansion into development-stage services and clinical support enhances its role in the medical device product lifecycle, contributing to higher revenue.

Additionally, Integer has focused on more profitable and fast-growing markets such as electrophysiology, heart structure, and neurovascular. Early-stage pre-market approval (PMA) projects are central to its business, constituting 80% of the company’s product pipeline.

Moreover, Integer’s growth strategy extends beyond internal developments, with strategic acquisitions playing a pivotal role. The recent acquisition of neurovascular catheter maker InNeuro marked the third in a series of acquisitions over the past few years. These acquisitions have exceeded internal expectations and notably enhanced the company’s profitability.

Valuation and Upside Potential:

Integer Holdings’ valuation appears favourable. Based on management’s revised EPS guidance, the stock is currently trading at a price-to-earnings (P/E) ratio of 19x, at the midpoint of the guidance. This represents an attractive valuation compared to the company’s historical P/E range, which fluctuated between 20x and 45x from 2020 to 2022.

Compared to other mid-cap peers in the healthcare equipment sector, Integer is trading at a substantial discount. The average P/E multiple for profitable peers in this group is 28x. Integer’s strong growth prospects and expansion into development-stage services warrant consideration for a premium valuation.

Overall, Integer Holdings Corporation’s stock shows potential for significant upside. If the company’s P/E ratio aligns with the group average over time, there is the potential for a 50% or more increase in its stock price. This suggests a promising outlook, reinforcing the belief in the potential of Integer Holdings as it advances in the medical device industry.